Hanmi Pharm한미약품
128940 · KOSPI · ₩128940 · 한미약품
₩350,500▼ ₩2,000 (0.57%)End-of-day · Oct 27, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩1.5T | ₩1.5T | ₩1.5T | ₩1.3T | ₩1.2T |
| Cost of sales | ₩663B | ₩678B | ₩662B | ₩613B | ₩570B |
| Gross profit | ₩884B | ₩817B | ₩829B | ₩719B | ₩633B |
| Operating income | ₩258B | ₩216B | ₩221B | ₩158B | ₩125B |
| Net income | ₩187B | ₩140B | ₩165B | ₩102B | ₩81B |
| Net income to shareholders | ₩170B | ₩121B | ₩146B | ₩83B | ₩67B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩2.1T | ₩2T | ₩1.9T | ₩1.9T | ₩1.9T |
| Current assets | ₩894B | ₩746B | ₩731B | ₩694B | ₩704B |
| Cash and equivalents | ₩108B | ₩192B | ₩55B | ₩147B | ₩209B |
| Total liabilities | ₩715B | ₩780B | ₩798B | ₩915B | ₩1T |
| Current liabilities | ₩605B | ₩683B | ₩705B | ₩677B | ₩649B |
| Borrowings | ₩425B | ₩488B | ₩563B | ₩667B | ₩691B |
| Total equity | ₩1.4T | ₩1.2T | ₩1.1T | ₩1T | ₩928B |
| Shareholders' equity | ₩1.2T | ₩1.1T | ₩955B | ₩872B | ₩803B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | ₩173B | ₩193B | ₩217B | ₩162B | ₩202B |
| Capital spending | ₩43B | ₩39B | ₩27B | ₩29B | ₩20B |
| Free cash flow | ₩130B | ₩154B | ₩189B | ₩133B | ₩182B |
| Dividends paid | ₩31B | ₩13B | ₩18B | ₩6B | ₩5.9B |
Consolidated where available. Amounts in won.
Also known as: Hanmi Pharm / 한미약품 / 128940 / KRX:128940
Source: KRX statistical information